Latest News

21 September 2015
Radiotherapy Associated with Improved Survival for High-Grade Sarcoma of the Extremity

Radiotherapy Associated with Improved Survival for High-Grade Sarcoma of the Extremity  

26 June 2012
Size Matters for Sarcomas!
Sarcoma Awareness Campaign: Targeting GPs in Birmingham with golf balls
23 May 2012
“Kick Sarcoma Day” comes to Parliament with Kevin Rudd and Paralympian Ellie Cole
 The Sarah Grace Sarcoma Foundation is marking “Kick Sarcoma Day” and making an announcement about the involvement of Australian Paralympic swimmer Ellie Cole in the Foundation.
6 May 2012
Results of a phase II study of sirolimus and cyclophosphamide in patients with advanced sarcoma
Schuetze SM et al. – Sirolimus and cyclophosphamide were tolerated by the majority of patients. About 20% of patients had stable sarcoma for at least 6months but objective tumour response was infrequent.
6 May 2012
ZIOPHARM Oncology, Inc. (ZIOP.OB) Reports Positive Preliminary Palifosfamide Overall Survival Data From Randomized Phase 2 Study in Soft Tissue Sarcoma
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP - News), a biopharmaceutical company with small molecule and synthetic biology approaches to new cancer therapies, announced today positive preliminary overall survival (OS) data from the Company's randomized, controlled Phase 2 trial of palifosfamide plus doxorubicin vs. doxorubicin alone (PICASSO) in patients with unresectable or metastatic soft tissue sarcoma.
5 May 2012
Votrient (Pazopanib) For Soft Tissue Sarcoma Approved By FDA
Votrient (pazopanib) has been approved by the FDA for the treatment of soft tissue sarcoma in patients who have already received chemotherapy. Soft tissue sarcoma is a type of cancer that starts in the fibrous tissue blood vessels, fat, muscle, or other supporting tissue in the body. The cancer develops in the mesenchymal cells. Votrient stops blood vessels that feed the tumor from growing and surviving - it stops angiogenesis.